Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

(2017) S. I. Sherman et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical biomarkers of response in advanced renal cell carcinoma

(2013) A. Ravaud et al.   ANNALS OF ONCOLOGY

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer

(2013) M Nishio et al.   BRITISH JOURNAL OF CANCER

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma

(2013) Charles S. Harmon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

The perivascular niche regulates breast tumour dormancy

(2013) Cyrus M. Ghajar et al.   NATURE CELL BIOLOGY

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues

(2013) Y. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-Term Follow-Up Evaluation of Results From Clinical Trial Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial Disease

(2012) Hirofumi Makino et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

(2012) Piotr Rutkowski et al.   BMC CANCER

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

(2012) D S Boss et al.   BRITISH JOURNAL OF CANCER

Model-based treatment optimization of a novel VEGFR inhibitor

(2012) Ron J. Keizer et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

(2012) Hajime Asahina et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

(2012) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy

(2012) Laura Horsley et al.   Expert Opinion on Drug Metabolism & Toxicology

The Dynamics of Angiogenic Factors and Their Soluble Receptors in Relation to Organ Dysfunction in Disseminated Intravascular Coagulation Associated with Sepsis

(2012) Subrina Jesmin et al.   INFLAMMATION

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

(2012) Annamaria Rapisarda et al.   Nature Reviews Clinical Oncology

Overcoming Antiangiogenic Resistance: Figure 1.

(2011) James C. Yao et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

(2011) K. Yamada et al.   CLINICAL CANCER RESEARCH

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

(2011) Yoshihiko Tomita et al.   EUROPEAN JOURNAL OF CANCER

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

(2011) Yutaka Fujiwara et al.   INVESTIGATIONAL NEW DRUGS

CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice

(2010) M. Noda et al.   BLOOD

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

(2010) Yasuhito Fujisaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

(2010) E. S. Robinson et al.   Clinical Journal of the American Society of Nephrology

Multiple functions of CXCL12 in a syngeneic model of breast cancer

(2010) Sharon A Williams et al.   Molecular Cancer

Serum hepatocyte growth factor levels and the effects of antidepressants in panic disorder

(2010) Masayuki Kanehisa et al.   NEUROPEPTIDES

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

(2009) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose-Dependent Increases in Circulating TGF-  and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

(2009) A. J. Mutsaers et al.   CLINICAL CANCER RESEARCH

E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles

(2009) K. Ikuta et al.   CLINICAL CANCER RESEARCH

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy

(2009) J. M. L. Ebos et al.   CLINICAL CANCER RESEARCH

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth

(2009) Romulo J C Albuquerque et al.   NATURE MEDICINE

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

(2008) J. Matsui et al.   CLINICAL CANCER RESEARCH